After receiving her bachelor's degree in Biochemistry and a master's degree in Health Sciences from the University of Minho, which introduced her to the field of immunology, Cardoso embarked upon a PhD in the laboratory of Henrique Veiga-Fernandes at the Champalimaud Foundation to study the role of neuro-immune interactions in metabolism.

Everything around a malignant tumour and its metastases, from its so-called microenvironment to the patients themselves as individuals, influences cancerous growth, and ultimately the outcome of the disease. This is the take-away message from CRSy2022 – the three-day international scientific symposium that took place at the Champalimaud Foundation, in Lisbon, from 19 to 21 October.

This public event, organised by the RAISE (Researchers in Action for Inclusion in Science and Education) consortium composed of the NGO Native Scientist, the Champalimaud Foundation and the Instituto de Medicina Molecular João Lobo Antunes (iMM), joined the 49 ERNs that took place in 25 European countries on the same date.

Organised by Broadreach Global with the European Brain Foundation (EBC), this summit will  bring together - in a collaborative, roundtable format - a highly diverse group of key opinion leaders, from  innovators, to decision-makers. 

When it comes to sexual competition, males have the star role. Clashing bodies, locking horns, biting and kicking are all considered fair play. Since these behaviours are so salient and robust, most studies focus on male behaviour, leaving females aside. 
 

The CaixaResearch Health Research Contest 2022 has selected 33 promising new biomedical and health projects promoted by research centres and universities in Spain and Portugal. Once again affirming that the “la Caixa” Foundation, in collaboration with BPI, supports projects of excellence that can have a positive impact on the health of citizens. 

Within this framework, it has allocated a total of 23.1 million euros to such projects – 20 Spanish and 13 Portuguese – that will be developed over the next three years. 

The statistics for pancreatic cancer are sobering. With a five-year survival rate of only 9%, incidence of the most common type, pancreatic ductal adenocarcinoma (PDAC), is growing and projected to be the second cause of cancer deaths by 2030. Surgery remains the most effective treatment, yet for 70-80% of patients, surgery is not a viable option. Understanding pancreatic cancer at the cellular and subcellular level is essential for developing therapies that can buy patients more time.
 

To know more about this research:

Digest

Scientific Article

One of the hallmarks of multiple myeloma (MM), a cancer of the bone marrow and one of the most frequent haematological cancers worldwide, is the disruption of the patients’ immune system, which allows the cancer to progress. Now, a study performed by Cristina João, who leads the Myeloma and Lymphoma Research Group at the Champalimaud Centre for the Unknown, and her colleagues, shows how so-called extracellular vesicles (EV’s) released by multiple myeloma cells can drive the disruption of the immune system.

To know more about this research:

Digest

Scientific Article